Lithium Carbonate ER

Published Online: Monday, March 1, 2004

Roxane Laboratories Inc (Columbus, Ohio) recently announced the approval of Lithium Carbonate Extended Release Tablets USP, 450 mg. This product is ABrated to GlaxoSmithKline?s Eskalith CR (lithium carbonate) 450 mg. Lithium Carbonate Extended Release Tablets are indicated for the treatment of manic episodes of manic?depressive illness. Maintenance therapy prevents or diminishes the intensity of subsequent episodes in those manic?depressive patients with a history of mania. The tablets may produce a normalization of symptomatology within 1 to 3 weeks. For more information, visit

Latest Articles
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
Chronic kidney disease incidence has grown faster than many of its common comorbidities such as diabetes and hypertension, and medications may be an underappreciated driver of this growth.
President Barack Obama’s fiscal year 2017 budget proposal calls for an additional $1.1 billion to combat the nation’s spiraling opioid epidemic.
Baxter International is voluntarily recalling intravenous solution due to leaking containers and the potential for particulate matter.
Latest Issues